Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2367-2373

  Dowell, Jonathan E ^a,c   Amirkhan, Robin H ^a,c   Lai, Wen S ^a,c   Frawley, William H ^b   Minna, John D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Angiogenesis; Lung neoplasms; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COHORT STUDIES; CYCLOOXYGENASE 2; ETOPOSIDE; FEMALE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444295111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
2. Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93: 1493-1495, 1996.
3. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
4. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
5. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A, Kondo T, Tanita T, Matsumura Y, Ono S, Saito Y and Sagawa M: Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer. Anticancer Res 19: 4305-4309, 1999.
6. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL and Gatter KC: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017-3024, 1998.
7. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
8. Ohta Y, Nozawa H, Tanaka Y, Oda M and Watanabe Y: Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 119: 804-813, 2000.
9. Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S and Watanabe Y: Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 68: 1034-1038, 1999.
10. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT and Yang PC: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89: 475-483, 2000.
11. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC and Lee YC: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432-441, 2001.
12. Toi M, Inada K, Suzuki H and Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36: 193-204, 1995.
13. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
14. O'Brien T, Cranston D, Fuggle S, Bicknell R and Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55: 510-513, 1995.
15. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
16. Lund EL, Thorsen C, Pedersen MW, Junker N and Kristjansen PE: Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 6: 4287-4291, 2000.
17. Salven P, Ruotsalainen T, Mattson K and Joensuu H: High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79: 144-146, 1998.
18. Ohta Y, Watanabe Y, Murakami S, Oda M, Hayashi Y, Nonomura A, Endo Y and Sasaki T: Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 76: 1041-1045, 1997.
19. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A and Angeletti CA: Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21: 1105-1110, 2002.
20. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
21. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
22. Chiabrando C, Broggini M, Castagnoli MN, Donelli MG, Noseda A, Visintainer M, Garattini S and Fanelli R: Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res 45: 3605-3608, 1985.
23. Young MR, Duffie GP, Lozano Y, Young ME and Wright MA: Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants. Cancer Res 50: 2973-2978, 1990.
24. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M and Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6: 2006-2011, 2000.
25. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999.
26. Rioux N and Castonguay A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58: 5354-5360, 1998.
27. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P and Moody TW: Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 18: 775-782 1998.
28. Ochiai M, Oguri T, Isobe T, Ishioka S and Yamakido M: Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 90: 1338-1343, 1999.
29. Watkins DN, Lenzo JC, Segal A, Garlepp MJ and Thompson PJ: Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 14: 412-418, 1999.
30. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
31. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T and Takahashi T: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5: 1001-1005, 1999.
32. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi T: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998.
33. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK and Xu XC: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7: 861-867, 2001.